SCHEMBL7663141

SCHEMBL7663141

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc(NC(=O)c2ccc3ccccc3c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR27 Q9NS67 1/20 0.59
ENPP1 P22413 5/20 0.57
ENPP2 Q13822 2/20 0.54
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
CASP3 P42574 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
ENPP3 O14638 4/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 2/20 0.50
LMNA P02545 2/20 0.50
KDM4E B2RXH2 2/20 0.50
DGAT1 O75907 1/20 0.50
MAPT P10636 1/20 0.50
DEGS1 O15121 1/20 0.50
KAT6A Q92794 1/20 0.49
NR1H4 Q96RI1 1/20 0.48
STAT3 P40763 1/20 0.47
PLAU P00749 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7663740 0.87 ALDH1A1 (0.65) MEN1KMT2AALDH1A1LMNA
SCHEMBL7582747 0.87 LMNA (0.65) MEN1KMT2AALDH1A1LMNA
SCHEMBL7666345 0.85 LMNA (0.57) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL7672669 0.84 LMNA (0.62) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL7299158 0.84 ACACB (0.60) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL7671404 0.84 GPR17 (0.59) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL7580808 0.84 HSD17B10 (0.61) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL5092484 0.84 MEN1 (0.55) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL7667880 0.84 LMNA (0.54) MEN1KMT2AALDH1A1LMNAKDM4E
SCHEMBL7672302 0.83 GPR27 (0.72) GPR27ENPP1ENPP2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed